Liver health and noninvasive assessment

NCT07878091 / Kylo-0603-IIa-01, first posted October 16. Shanghai Chia Tai Tianqing sponsors a masked randomized Phase 2a trial in 120 adults with MASLD and overweight/obesity in China, comparing daily oral Kylo-0603 8, 12 or 16 mg with placebo for 12 weeks.

Kylo-0603 is described as a liver-targeted GalNAc-conjugated thyroid-hormone receptor β agonist. Primary is percentage change in MRI-PDFF liver-fat content at week 12. Secondary measures include liver stiffness, LDL cholesterol, liver enzymes and other biomarkers. Neither liver-fat reduction nor a stiffness/LDL change alone establishes fibrosis reversal, fewer liver complications or cardiovascular benefit.

The record is not yet recruiting. Start November 15, 2026 and primary/final completion August 15, 2027 are estimates; no results or participant adverse-event rates are posted. Earlier healthy-volunteer work is historical context, not a new October efficacy result. No U.S. approval or availability is established.

Sources: ClinicalTrials.gov · NCT07878091; www1.hkexnews.hk · PDF document.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered September 5–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 144 records across 2 pages of the bounded ClinicalTrials.gov query, plus 13 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new Kylo-0603 patient trial is the selected formal entrant. Prior TRUTH, ARO-INHBE, ALN-CIDEB and efimosfermin findings were deduplicated. Current EMA Wegovy overview still does not resolve the saved September MASH variation; no approval/rejection inferred from omission. Full papers/supplements, clinical-outcomes and noninvasive-test utility census remain gaps.

Informal-source coverage: Saved Wegovy CHMP omission inference revisited against EMA current page; outcome remains unconfirmed and no repeat alert. Targeted informal searches supplied no separate new original claim selected. Complete conference/investor audio and informal source census remain incomplete.

Full coverage record.

Baseline recovery, checked October 13 — NEBULA-1, NCT07701993 / GSK 306300. GSK's randomized masked placebo-controlled Phase 3 trial plans 1,740 adults aged 18–75 with compensated MASH cirrhosis. Efimosfermin alfa is an investigational FGF21 analogue given subcutaneously.

Primary is time to an adjudicated composite of all-cause mortality, liver transplantation and significant hepatic decompensation, over up to 356 weeks. Liver stiffness, ELF, metabolic measures, quality of life and harms are secondary; biomarker improvement alone will not prove this primary benefit.

The September 30 registry and original GSK protocol say recruiting, with actual start July 22, 2026. Estimated primary completion is June 23, 2033, final August 24, 2033. No results; U.S. treatment remains investigational. This earlier program fills a saved coverage gap rather than a new October launch.

A secondary CTIS mirror displays an October 12 EU authorization date and a different 1,468 planned total; the primary EMA linked search did not expose the decision details. That regional claim/count is not promoted as verified or substituted for the source-backed 1,740 protocol count.

Sources: ClinicalTrials.gov · NCT07701993; gsk-studyregister.com · source page; euclinicaltrials.eu · source page; GSK Q1 2026 update.

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 138 records across 2 pages; incidental studies excluded. Named topic records refreshed: 12. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; EMA current Wegovy overview and available minutes still do not resolve the September MASH variation. September minutes expected after the October CHMP; no rejection/delay inferred from omission. Secondary CTIS mirror NEBULA authorization not independently established from primary EMA; record discrepancy retained. Worldwide fibrosis/noninvasive utility and complete FGF21 harms corpus remain incomplete.

Informal-source coverage: Revisited saved September 18 Reddit inference about Wegovy CHMP omission against current EMA page and available agendas/minutes. Outcome remains unconfirmed; no repeat alert. Searched MASH informal development claims without selecting a new attributable original signal; full audio remains incomplete.

Full coverage record.

TRUTH / NCT05506488, published October 1; recovered in this October 9 overlap review. Amsterdam investigators randomized 31 people with fibrotic MASH (F2–F3) to intermittent dasatinib plus quercetin or placebo for 21 weeks.

Fibrosis improvement without MASH worsening occurred in 8/17 (47%) versus 1/14 (7%): risk difference 40 percentage points (95% CI 8.2–64.5), reported p=0.021. The reported risk ratio was 6.59 (95% CI 0.93–46.53); preserve this wide interval despite the different p-value method. MASH resolution was 9/17 (53%) versus 1/14 (7%), risk difference 46 points (95% CI 13.6–69.3).

Adverse events occurred in 82% versus 43%; one active participant stopped because of GI symptoms/fatigue. One serious event, planned knee surgery, was considered unrelated; severe dysphagia was attributed to previously undisclosed malignancy and that participant withdrew. Diabetes prevalence was imbalanced (76.5% versus 35.7%). Small size, short follow-up and biopsy surrogates limit inference: this does not establish fewer liver complications, a durable cure or lifespan extension. The combination has no U.S. MASH/longevity approval. Larger replication timing is undated.

Additional limitations: Four participants lacked follow-up biopsy and were counted as nonresponders in the primary analysis. A worst-case missing-data sensitivity gave RR 3.29 (95% CI 0.83–13.08), p=0.068. Noninvasive FIB-4, ELF and liver-stiffness comparisons were not significant. Histologic response is hypothesis-generating pending larger replication.

Sources: Primary source 1; Primary source 2.

Remaining gaps: Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Liver discovery returned 171 records; first 100 downloaded; selected relevant records screened, remaining page not reviewed. Updated saved RNA-interference protocols rechecked. September 29 TRIUMPH-1 full methods/CI access gap and worldwide noninvasive-screening/approval coverage remain.

Informal-source coverage: October 9 original r/Futurology post located: https://www.reddit.com/r/Futurology/comments/1x1lwvz/in_a_world_first_in_a_phase_2_trial_with_31/ . It frames histologic MASH resolution as a 50+% cure rate; original trial supports a short-term biopsy outcome, not proven durable cure. This is interpretation of a published paper, not a new clinical leak. Wider podcast audio and existing European Wegovy-MASH rumor not comprehensively refreshed.

Full coverage record.

Source/event date: October 6, 2026. Evidence: new phase 2 registration. AROINHBE-2001 plans 252 adults with suspected MASH, BMI 30–50, with or without diabetes and with stable background GLP-1/GIP therapy allowed. Randomized double-masked ARO-INHBE dose/schedule groups are compared with matched placebo. The primary endpoint is MRI-PDFF liver-fat change at week 48; histologic MASH resolution and fibrosis improvement are secondary. NOT_YET_RECRUITING; September 2026 start is still estimated and elapsed. Primary/final completion is estimated October 2029. No human results or safety estimates are posted. Registration establishes a liver development plan, not proven fibrosis benefit, fewer complications or U.S. approval.

ClinicalTrials.gov · NCT07859813 · ClinicalTrials.gov · NCT07859813

Source/event date: October 2, 2026. Evidence: new phase 3 registration. Regeneron’s ALN-CIDEB-MASLD-2604 plans 1,500 adults with MASLD and FibroScan liver stiffness 6–20 kPa. The randomized quadruple-masked study compares two ALN-CIDEB dose levels with placebo. Registered primary endpoints are incidence and severity of treatment-emergent adverse events through week 64; week-52 FibroScan fat/stiffness and liver enzymes are secondary. NOT_YET_RECRUITING, with November 6, 2026 estimated start and March 3, 2029 completion.

This registration does not show new human efficacy, clinical-event prevention, marketing approval or first dosing. MASLD inclusion by noninvasive stiffness is distinct from a biopsy-confirmed F2–F3 MASH pivotal population. The large phase designation does not convert biomarkers into clinical benefit; no results are posted.

ClinicalTrials.gov · NCT07854782 · ClinicalTrials.gov · NCT07854782

Source/event date: 2026-09-28. Evidence: Professional-society clinical guidance; not a new trial.

The September 28 EASL–EASD–EASO guidance addresses selection, initiation, monitoring and stopping of resmetirom and weekly semaglutide 2.4 mg as MASH-targeted treatments. It recommends individualizing choice by metabolic disease, body composition, other conditions and preferences; the strength of the recommendation should not be mistaken for high-certainty comparative evidence. This is an interpretation of existing evidence, not a new randomized head-to-head trial or proof of reduced liver-related deaths. Existing U.S. indications remain separate from European review and access. The guidance does not resolve the previously tracked September CHMP outcome. Further clinical-outcome follow-up remains necessary.

Next milestone: NATiV3 Q4 2026 sponsor forecast; ESSENCE clinical-event follow-up remains ongoing.

journal-of-hepatology.eu · article.

Related findings:

• DR10624 adds a triglyceride trial in diabetic kidney disease.

Source date: 2026-09-23. Event date: exact date not disclosed. Date basis: Announcement date; exact HSA action date not independently verified. Evidence: Sponsor announcement of regulatory approval.

Novo announced HSA approval of weekly injectable semaglutide 2.4 mg for adults with noncirrhotic MASH and F2–F3 fibrosis, with diet and activity. The decision draws on the existing ESSENCE week-72 biopsy evidence, not a newly completed outcomes trial.

Limitations: Not an indication for cirrhosis; geographic approval does not imply local stock or reimbursement. Liver-fat or biopsy improvement is separate from preventing decompensation, transplant or death. HSA decision letter was not independently retrieved.

Safety: No new safety analysis; known gastrointestinal tolerability and indication-specific prescribing information remain relevant.

U.S. status: Existing U.S. MASH approval is separate and unchanged.

Next milestone: ESSENCE part 2 continues to 240 weeks for liver-related clinical events; this release does not give a new readout date.

Novo Singapore approval announcement.

Source date: 2026-09-21. Event date: 2026-09-21. Evidence: Sponsor development forecast.

Novo plans a Phase 3 MASH program for UBT251 and a dedicated efruxifermin alcohol-related liver disease trial during 2027. The CMD presentation places UBT251 in F2–F3 disease and efruxifermin in advanced fibrosis/compensated cirrhosis. Existing SYNCHRONY OUTCOME results are forecast around 2030.

Limitations: Plans do not establish initiation or clinical benefit in the new indications. Historical efruxifermin biopsy data displayed in the presentation are not new September results.

Safety: No new safety dataset for the planned programs.

U.S. status: No U.S. approval established for UBT251 or efruxifermin.

Next milestone: UBT251 Phase 3 MASH and efruxifermin ALD study initiation: 2027 sponsor forecasts; specific dates and identifiers pending.

Novo Cardiovascular and liver CMD, slides 10, 18–19.

Source date: 2026-09-03. Evidence: Historical evidence recovered.

TGM-312 adds a liver-targeted SLC25A5 RNAi program to the watch. The phase 1/2 RESTORE-MASH study advanced from single-dose cohorts of healthy volunteers to multiple-dose cohorts of patients with MASH after a monitoring review. Four healthy-volunteer cohorts had been dosed; the participant count was not reported.

Limitations: No numerical human liver-efficacy findings were provided. Preclinical combination and fibrosis results remain animal evidence. The registry identifier was not verified.

Safety: The sponsor reports no serious or severe adverse events in the healthy-volunteer cohorts; this is limited early safety evidence.

U.S. status: Investigational.

Next milestone: The sponsor forecasts interim results from MASH patient cohorts during 2027.

Tangram September3 original release.

Source/event date: 2026-08-03. Date basis: Sponsor enrollment-initiation announcement. Evidence: Historical development baseline; not October news or a new efficacy readout.

Altimmune announced that enrollment had begun in PERFORMA, a global randomized, double-blind, placebo-controlled phase 3 trial of pemvidutide in MASH with moderate to advanced fibrosis. The program will assess fibrosis improvement, MASH resolution and clinical outcomes. Its current sponsor pipeline also describes active enrollment. This establishes a later MASH development stage than the older IMPACT phase 2b evidence; the obesity MOMENTUM results remain a separate indication and study.

Limitations and safety: Initiation does not establish efficacy, fewer liver complications or long-term safety. Histology and biomarkers remain distinct from clinical outcomes; the announcement is sponsor evidence, with no new outcome effect estimate. Breakthrough Therapy designation is not marketing approval.

U.S. status: Investigational; no pemvidutide approval established.

Next milestone: PERFORMA 52-week data forecast for 2029 by the sponsor, not a guaranteed publication or approval date.

Altimmune August 3 primary announcement; Current sponsor pipeline.